

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the month of March 2024**

Commission File Number: **001-39950**

**Evaxion Biotech A/S**  
(Translation of registrant's name into English)

**Dr. Neergaards Vej 5f**  
**DK-2970 Hoersholm**  
**Denmark**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]    Form 40-F [   ]

---

## INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S's registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050) and Form F-1 (File No. 333-276505), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

### Press Release

On March 19, 2024, Evaxion Biotech A/S (the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled 'Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform'. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

### Exhibits

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

<a href="#">99.1</a>	<a href="#">Press Release dated March 19, 2024</a>
----------------------	--

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Evaxion Biotech A/S**  
(Registrant)

Date: March 19, 2024

By: /s/ Christian Kanstrup  
Christian Kanstrup  
Chief Executive Officer

## Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

- The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologies
- AI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needs
- With a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needs
- The potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine collaboration with MSD

COPENHAGEN, Denmark, March 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today hosts a Research & Development (R&D) Day focusing on its core AI-Immunology™ platform. The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here.

The R&D Day features a series of talks providing in-depth insights into Evaxion's clinically validated AI-Immunology™ platform for vaccine target discovery, design and development. AI-Immunology™ consists of a collection of in-house developed AI building blocks that can be intelligently combined into AI prediction models to address complex healthcare issues related to the immune system. With the AI prediction models, PIONEER™, ObsERV™, EDEN™ and RAVEN™, we can identify clinically relevant vaccine targets within hours.

Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: “We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives. We believe that we hold a truly differentiated position driven by our validated AI-Immunology™ platform and the multi-disciplinary capability set we have built around it. The potential of AI-Immunology™ is evidenced by our strong pipeline of vaccine candidates and existing partnerships.”

The presentations during the day will, among other things, cover:

- The innovative modular architecture of AI-Immunology™, where AI building blocks can be combined into AI prediction models, enhancing scalability
- Insights into the novel AI-Immunology™ building block, **EvaxMHC**, which is used across the platform, significantly enhancing the predictive capabilities
- The clinical validation of the predictive capabilities of the **PIONEER™** model showing a statistically significant improvement in progression-free survival in metastatic melanoma patients
- The novel tumor target sources, named Endogenous Retroviruses (ERVs), showing high relevance in low tumor mutation burden cancers, allowing for potentially more effective personal cancer vaccines
- The **EDEN™** model outperforms reverse vaccinology finding novel targets in hours instead of years. The EDEN™ designed EVX-B2 vaccine candidate showing stronger protection than a vaccine candidate developed by GSK's Gonorrhea
- **RAVEN™** introduces novel vaccine concepts to enhance the effectiveness of T-cell-based vaccines
- The **ObsERV™** model allows for a novel precision vaccine approach toward addressing cancers which cannot be targeted with standard immunotherapies

Following the R&D Day, a replay of the event presentations will be available on our website.

### About AI-Immunology™

AI-Immunology™ is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of proprietary AI models PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity of the patient's immune system. AI-Immunology™ advanced computational modelling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic and personalized approach to combat fast-evolving pathogens and malignant cells.

### About EVAXION

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please [visit our website](#).

### Forward-Looking Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at [www.sec.gov](http://www.sec.gov). We do not assume any obligation to update any forward-looking statements except as required by law.

#### Contact Information

Evaxion Biotech A/S

Christian Kanstrup

Chief Executive Officer

[cka@evaxion-biotech.com](mailto:cka@evaxion-biotech.com)

Source: Evaxion Biotech